Drug intelligence / Profile preview

MORAb-050

Development stage: Preclinical
Lead developer: Creative Biolabs
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MORAb-050 is a fully human IgM monoclonal antibody developed by Morphotek (a subsidiary of Eisai) in collaboration with the Ludwig Institute for Cancer Research. It is designed to target ganglioside GM3, a glycosphingolipid that is highly expressed on the surface of various cancer cells, particularly in metastatic melanoma. As an IgM antibody, MORAb-050 is intended to leverage the high avidity and potent complement-activating properties characteristic of the IgM isotype to induce tumor cell lysis. The program reached the IND-enabling phase for the treatment of metastatic melanoma.

Targets

GM3 (Ganglioside GM3)

Beyond the preview

Go deeper on MORAb-050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MORAb-050.

Explore the full profile